Abstract 2815
Background
Pathologic complete response after neoadjuvant chemotherapy is considered as a surrogate of survival by most authors, although there are special phenotypes, such HER2 positive, where their potential as apredictor of survival is stronger.
Methods
Overall survival was analyzed according to pathologic response in a cohort of early breast cancer patients (all subtypes) treated with standard neoadjuvant chemotherapy. Between March 2000 to October 2016, 459 breast cancer patients were treated with neoadjuvant chemotherapy with anthracicline and taxane regimens.
Results
Median age was 52 (range 28-87), 173 tumors (38%) were classifyed as HER2 positive, 148 (32%) triple negative and 138 (30%) as luminal breast cancer. Median initial size was 34 mm (10-100) and 237 patients (51%) had initial node involvement. We achieved a total of 152/459 complete pathologic response with a 43% rate in HER2 positive, 44% in triple negative and 9% in luminal breast cancer patientes. Ten years disease free survival in the whole serie was 83%, with a 72% for patients without complete pathologic response versus 90% for complete pathologic response (long rang <0,00001). A strong correlation between pathologic response and survival wass found in all subtypes (long rang p:0,033; 0,028 and 0,027 in HER2 positive, luminal and triple negative respectively). A table with survival results according the RCB response by Symmans method in the whole series and different phenotypes is attached.Table: 264P
| Phenotype | RCB type 0 | RCB1 type I | RCB type II | RCB type III |
|---|---|---|---|---|
| Overall | Median DFS:167 HR: 1 | Median DFS:156 HR: 2,6 | Median DFS:130 HR: 4,5 | Median DFS:85 HR: 9,6 |
| HER 2 positive | Median DFS: 126 HR: 1 | Median DFS: 90 HR: 1,6 | Median DFS:100 HR: 2,5 | Median DFS:96 HR: 4,4 |
| Luminal | Median DFS: 176 HR: 1 | Median DFS: 160 HR: 2,8 | Median DFS:115 HR: 4,8 | Median DFS: NA HR: NA |
| Triple negative | Median DFS:188 HR: 1 | Median DFS: 141 HR: 8,8 | Median DFS: 117 HR: 16,7 | Median DFS:122 HR: 28.4 |
Conclusions
Pathologic response is a strong predictor of overall survival in all breast cancer phenotypes althoug in the triple negative has the highest magnitude with a HR of 28,4 in patients with worse pathologic response (RCB type III). Neoadjuvant chemotherapy should be considered in the majority of patients who are candidates to chemotherapy, specially in triple negative and HER2 positive; however, in luminal phenotype a better selection for neoadyuvant chemotherapy is needed.
Clinical trial identification
Legal entity responsible for the study
Hospital Universitari Arnau de Vilanova.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract